Cogent Biosciences, Inc.
cogentbio.comWhat Do They Do?
Develops bezuclastinib and other precision therapies for patients with systemic mastocytosis, gastrointestinal stromal tumors and other genetically defined diseases.
10-K for FY2025, filed Feb 17, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
−$96.4MView ↗
- ▲ +31% (Loss)
- vs −$73.5M in Q2 FY2025
Commercial preparation
The earlier report said the company was preparing to commercialize bezuclastinib if trials showed clinical benefit; the latest describes an internal commercial organization and a planned U.S. launch, pending approval.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Feb 17, 2026Prepare to commercialize bezuclastinib should any or all of the planned clinical trials demonstrate clinical benefit for patients with high…View ↗
We are a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. Our approach is…View ↗
Broader pipeline
The earlier report described a research portfolio focused on FGFR and ErbB targets; the latest also describes research programs in additional cancer targets.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Feb 17, 2026We are a biotechnology company focused on developing precision therapies for genetically defined diseases. Our approach is to design…View ↗
Our research team is also developing a potential best-in-class, wild-type-sparing, PI3Kα inhibitor that provides coverage of both the…View ↗
Our research team is developing a potent and selective KRAS inhibitor. Mutations in KRAS are among the most prevalent mutations found in…View ↗
Our research team is developing a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor. The JAK2 V617F mutation is the most…View ↗
Programs enter clinical testing
The earlier report described the FGFR and ErbB programs as preclinical; the latest says both have moved into clinical studies.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Feb 17, 2026Advance our FGFR2 and ErbB2 preclinical programs, as well as our other undisclosed preclinical programs; andView ↗
Who Do They Compete With?
Competes with Blueprint Medicines, Novartis, Pfizer, Bayer HealthCare Pharmaceuticals, Deciphera Pharmaceuticals, Taiho Pharmaceutical, GSK, Incyte, Taiho Pharma, Elevar Therapeutics, TransThera Sciences (Nanjing), Tyra Biosciences, Abbisko Therapeutics, HutchMed (China), and Amgen
10-K for FY2025, filed Feb 17, 2026In SM approved therapies are limited. Blueprint Medicines' (a Sanofi company) avapritinib and Novartis AG’s midostaurin are approved for…View ↗
Loading...
